News on NGS technologies, RNA-seq, clinical sequencing, & sample prep in genetics, genomics, and molecular diagnostics.
The study authors cautioned that immunological signatures cannot be predicted from tumor mutational burden or microenvironment analysis of a single biopsy alone.
The company no longer plans to develop cell-free DNA assays for oncology but will instead look to commercialize a new target capture technology.
The company said it will use the award to further develop its ImmuneProfiler neoantigen prediction technology for personalized cancer medicine.
Researchers found 253 candidate disease genes, based on 10,927 exomes from patients with autism spectrum disorder, developmental delay, or intellectual disability.
A multi-omic analysis implicated a handful of transcription factors, along with genes and regulatory RNAs down- and upstream of them, in metastatic colorectal cancer.
